Independent · evidence-based · non-judgmentalDraft · pending medical review
Not yet medically reviewed — information on this site is in preparation and has not been verified by a medical reviewer.
Drug index / Depressant / GBL
Depressant

GBL

oxolan-2-one

GBL is an industrial solvent that the body converts into GHB; it is a depressant with the same dangers as GHB — overdose, dependence, and lethal interaction with alcohol — and acts faster.

Overview

GBL (gamma-butyrolactone) is an industrial chemical and solvent that the body rapidly converts into GHB after it is swallowed, so its effects are essentially those of GHB. Because of this, GBL is used as a 'prodrug' substitute for GHB and carries all the same dangers, with some made worse: GBL is absorbed faster and is more potent by volume than GHB, so the margin between a recreational amount and a dangerous one is even narrower and harder to judge. Like GHB it is a central nervous system depressant, it has a steep dose-response curve, it is strongly associated with dependence, and it is extremely dangerous in combination with alcohol. It is encountered as a liquid and is sometimes sold under the guise of its industrial uses.

Source: DEA; EMCDDA; PubChem CID 7302

Chemistry & mechanism of action

GBL itself is largely inactive until the body converts it — quickly, via enzymes in the blood and tissues — into GHB, which is the actual active drug. GHB then acts as a central nervous system depressant, affecting GABA-B and dedicated GHB receptors to produce sedation and, at higher doses, deep unconsciousness and suppression of breathing. Because GBL is converted rapidly and is absorbed faster than GHB, its effects come on quicker and the dose needed is smaller, which makes accidental overdose easier. The same depressant mechanism is why combining it with other depressants — above all alcohol — is so dangerous. Repeated use produces tolerance and a physical dependence whose withdrawal can be severe.

Source: DEA; PubChem CID 7302

Effects

Because it becomes GHB in the body, GBL produces the same effects: at lower doses, relaxation, euphoria, reduced inhibition, and sociability; as the dose rises, drowsiness, dizziness, nausea, confusion, and loss of coordination. The crucial problem is the steep, unpredictable dose-response — a small increase in amount can tip a person from a recreational effect into deep sedation, unconsciousness, dangerously slowed breathing, and coma. Because GBL is more potent by volume and faster-acting than GHB, this transition can happen quickly and with very small differences in dose. Repeated use leads to tolerance and dependence, and frequent users can develop a severe withdrawal syndrome when they stop.

Source: DEA; EMCDDA

Risks & harms

GBL carries all of GHB's dangers, several intensified. The dose-response curve is steep and unpredictable, and because GBL is more potent by volume and faster-acting, the gap between a desired effect and overdose is very narrow — overdose can bring deep unconsciousness, dangerously slowed breathing, vomiting with a risk of choking, seizures, and coma. The single most dangerous combination is with alcohol (or other depressants): together they multiply the suppression of breathing and have caused many deaths. There is no reversal agent; an overdose is a medical emergency requiring 911 and careful airway management — someone who is heavily sedated should never be left alone to 'sleep it off,' and should be placed on their side to reduce choking risk. Heavy regular use produces physical dependence, and GBL/GHB withdrawal can be severe and medically dangerous — including agitation, confusion, and seizures — and should be managed with medical support, not stopped abruptly alone. For poisoning guidance call Poison Control at 1-800-222-1222; for substance-use support the SAMHSA National Helpline is 1-800-662-4357.

Source: DEA; EMCDDA; SAMHSA

Images

Visual references coming soon.

If it’s too intense

If an experience becomes overwhelming, the goal is to stay safe and let it pass — most difficult experiences ease as the drug wears off.

  • Get to a calm, safe space with someone you trust who is sober and can stay with you.
  • Cool down if you’re overheating — move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
  • Sip water to thirst — but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
  • Slow your breathing — long, slow exhales help settle a racing heart and anxiety.
  • A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
  • Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.

With depressants, the danger is over-sedation: if someone is very drowsy, hard to wake, or breathing slowly, treat it as an emergency.

Call 911 (or Poison Control, 1-800-222-1222) right away for chest pain, a very high body temperature, a seizure, unconsciousness, or severe confusion. These are medical emergencies, not something to wait out.

Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft — not yet medically reviewed.

Forensic dossier

Draft · every field is source-cited or marked “Unknown — pending review”

Identity

InChIKey
YEJRWHAVMIAJKC-UHFFFAOYSA-NPubChem PUG-REST · retrieved 2026-06-18
Synonyms / aliases
blue nitro, gamma-Butyrolactone, BUTYROLACTONE, dihydrofuran-2(3H)-one, 4-Butyrolactone, 4-Butanolide, 1,4-Butanolide, 4-Hydroxybutyric acid lactone, 2-Oxolanone, Dihydro-2(3H)-furanone, oxolan-2-onePubChem PUG-REST + seed aliases · retrieved 2026-06-18

Composition

Composition
N/A — single compound (see Identity)

Physical / pill characteristics

Dosage form
Unknown — pending review
Route
Unknown — pending review
Shape
Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Color
Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Imprint
Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Score
Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)

Scheduling & legal status

US schedule
Unknown — pending review
International
See EMCDDA/EUDA + WHO — synthesize per jurisdictionEMCDDA / EUDA · retrieved 2026-06-18

Effects

Effects
Cited source pending synthesis — author in our words from NIDA/MedlinePlus on review (NOT auto-generated)NIDA + MedlinePlus · retrieved 2026-06-18

Risks

Risks
Cited source pending synthesis — author in our words from NIDA/MedlinePlus on review (NOT auto-generated)NIDA + MedlinePlus · retrieved 2026-06-18

Interactions

Interactions
See DailyMed label §Drug Interactions (Rx) — synthesize + cite per itemDailyMed SPL §Drug Interactions · retrieved 2026-06-18

Dosage

Pending medical reviewer

Sources

← Back to the drug index